Introduction
============

Lysosomal storage disorders (LSDs) comprise a heterogeneous group of at least 50 rare genetic disorders caused by progressive accumulation of specific substrates, generally due to a deficiency of a lysosomal enzyme ([@B8]). A main factor related to diagnosis delay is the wide spectrum of clinical manifestations of variable severity that are not specific of the disorder and can overlap with symptoms of other LSDs ([@B25]; [@B14]). Another challenge is the high allelic heterogeneity for genetic screening. Early diagnosis is important since enzyme replacement and other available therapies improve the natural course of many of these diseases ([@B23]; [@B17]; [@B9]; [@B11]).

The established approach to the diagnosis of patients with LSDs include the detection of the accumulated substrate whenever possible and the activity assay of the deficient enzyme, followed by Sanger sequencing of the gene associated with the disorder, which can be expensive and time consuming ([@B26]). Fortunately, new technologies are becoming more accessible and relatively affordable for the diagnostic routine. Targeted next-generation sequencing (TNGS) allows the simultaneous screening of several LSDs-related genes, with great depth of coverage, manageable interpretation, and relative low risk of finding variants of unknown significance, decreasing turnaround times for the final report ([@B18]; [@B2]).

However, before using TNGS technologies as a diagnostic tool, the validation of each test offered in the clinical setting is required. This validation is essential for stablishing critical parameters, from sample processing to analysis and interpretation steps, following the recommendations of published guidelines ([@B10]; [@B18]).

Here, we present the development and validation of two different TNGS panels of genes related to a subgroup of LSDs, offered as a diagnostic alternative by a Brazilian reference service for rare diseases. The sensitivity, advantages, drawbacks, and clinical utility of these TNGS panels are then reported.

Subjects and Methods
====================

Gene panel design
-----------------

Genes associated with LSDs with overlapping clinical manifestations, as well as related deficiencies were included in our panels ([Figure 1](#f1){ref-type="fig"}). The two panels comprised 11 genes: Panel A: *GLA* (Fabry disease), *NAGA* (Schindler disease), *GAA* (Pompe disease), and *LAMP2* (Danon disease), and Panel B: *NPC1* (Niemann-Pick disease type C1), *NPC2* (Niemann-Pick disease type C2), *GBA1* (Gaucher disease)*, LIPA* (Lysosomal acid lipase deficiency)*, SMPD1* (Niemann-Pick disease type A/B), *CHIT1* (Chitotriosidase deficiency), and *PSAP* (Prosaposin deficiency and saposin B deficiency). Custom primers were designed using Ion Ampliseq^TM^ Designer v3.4 (Thermo Fisher Scientific) to generate a pool of primers for amplification of genomic regions of interest. Each one consists of two primer pools that target the entire coding region, including 20 bp of intron-exon junctions. Missed areas in the design were filled in by Sanger sequencing to reach a 100% breadth of coverage.

![Overlapping of clinical manifestations among LSDs. Venn's four-set diagram represented by causal genes. A, Panel A. B, Panel B.](1415-4757-GMB-1678-4685-GMB-2018-0092-gf01){#f1}

Subjects
--------

The validation phase was performed using whole blood genomic DNA extracted by a standard saline extraction method ([@B16]), from 55 diagnosed patients (22 for panel A and 33 for panel B) who underwent previous investigation with biochemical tests and Sanger sequencing (with known mutations and polymorphisms, including SNPs and small *indels*). Samples from three healthy adults were also analyzed. All probands were recruited from patients attended at the Medical Genetic Service, Hospital de Clinicas de Porto Alegre, Brazil. All samples were anonymized, sequenced, and analyzed in a single blind manner. TNGS was performed using an Ion Torrent Personal Genome Machine^TM^ (PGM^TM^) System (Thermo Fisher Scientific). The clinical utility of the validated tests was assessed by evaluating four patients with suspected LSDs. The study was approved by the institutional Ethics Committee of HCPA (\#15-0165).

Multiplex PCR enrichment, library construction, and massive parallel sequencing
-------------------------------------------------------------------------------

The reagents used in these analyses were from Thermo Fisher Scientific, unless otherwise stated. Twenty nanograms of each gDNA sample were used for PCR enrichment of targets by applying the two custom Ampliseq^TM^ panels. Each panel consisted of two separate PCR primer pools. The library was constructed using Ion AmpliSeq Library kit 2.0. Eight to nine samples barcoded with Ion Xpress Barcode Adapters kit were included in each set of library preparations. Unamplified libraries were purified with an Agencourt AMPure XP kit (Beckman Coulter). Libraries were prepared in equimolar concentrations using the Ion Library Equalizer kit, or quantified using the Qubit^®^ dsDNA HS kit, followed by dilution to the same concentration. For template preparation, the barcoded libraries were pooled in equimolar concentrations of 100 pM each and were subsequently submitted to emulsion PCR (emPCR) using the Ion PGM Template OT2 200 kit on the Ion OneTouch2 Instrument (Thermo Fisher Scientific). The percentage of positive Ion Sphere Particles (ISPs) was defined by flow cytometry performed on an Attune^®^ Acoustic Focusing Flow Cytometer (Thermo Fisher Scientific) according to the demonstrated protocol (Part. no. 4477181). Positive ISPs were enriched using Ion OneTouch ES (Enrichment System).

All barcoded samples were loaded onto Ion 314^TM^ chips v2 (Thermo Fisher Scientific) taking up to 8-9 samples on a single chip per sequencing run. Chip loading was performed according to the user guide for the Ion PGM sequencing 200 kit v2 (Thermo Fisher Scientific), following the manufacturer's instruction.

Data analysis
-------------

Raw signal data were analyzed using Torrent Suite Software v.5.0 (Thermo Fisher Scientific). Primary analyses included signal processing, base calling, demultiplexing, read alignment to human genome reference 19 (Genome Reference Consortium GRCh37), quality control of mapping quality, coverage analysis, and variant calling. Subsequently, a list of detected sequence variants, including SNPs and small insertions/deletions, was imported into Ion Reporter^TM^ Software (Thermo Fisher Scientific) for annotation. Alignments were visually verified with the Integrative Genomics Viewer (IGV) v2.3 ([@B20]).

Candidate variants met the following criteria: be detected on both strands and account for 20% of total reads at that site, quality score ≥ 20, minimum read depth of 100X and variant frequency in the population ≤ 1%. The filtered variants were then compared to mutation databases, including dbSNP (htpp://www.ncbi.nlm.nih.gov/projects/SNP/), 1000G (http://browser.1000genomes.org), ExAC (http://exac.broadinstitute.org), Online Archive of Brazilian Mutations (http://abraom.ib.usp.br/), HGMD (http://www.hgmd.cf.ac.uk/ac/), Pompe Center at Erasmus Medical Center (http://www.pompecenter.nl/), Fabry-database.org (http://fabry-database.org/), and the International Niemann-Pick Rare Disease Registry (https://inpdr.org/). All databases were last accessed in September 2017. Evaluation of the pathogenicity of the novel variants of unknown significance (VUS) (i.e., not found in any of the mutation databases, or not previously described in the literature) were analyzed with *in silico* web tools, such as SIFT ([@B12]; [@B22]), Polyphen-2 ([@B1]), and Mutation Taster ([@B21]), to predict potential protein deleterious effects on protein function. To evaluate the possible effect of synonymous variant in gene splicing, we used the Human Splicer Finding web tool ([@B5]). Indels were analyzed by VEST (Variant Effect Scoring Tool), VEP (Vep Effect Predictor), as well as Mutation Taster ([@B3]; [@B6]; [@B15]). Nonsense, frameshift, and canonical splice mutations were classified automatically as pathogenic ([@B19]).

Performance characteristics
---------------------------

Run metrics and coverage analyses were performed to identify systematic deficiencies. We analyzed depth of coverage (DoC) in the targeted amplicons to assess target enrichment across all 58 samples data sets and establish an acceptable reference range for key measures.

Two coverage analyses were generated: (1) High-level DoC overview plot based on [@B24], with relative DoC in the y-axis and amplicons on the x-axis, highlighting in red the amplicons with significantly lower coverage ([Figure 2](#f2){ref-type="fig"}); and [(2)](#f2){ref-type="fig"} relative DoC plot of exons per gene (Supplementary Figures S1 and S2). Direct visual inspection of amplicon reads on IGV v2.3 and evaluation of high-level DoC coverage overview were used to establish the reportable ranges for each panel.

![Depth of Coverage (DoC) of panels presented in this study. Overview of all 191 custom amplicons designed for Panel A (73 amplicons) (upper panel A) and Panel B (118 amplicons) (lower panel B) for TNGS. The line indicates a DoC of 100X. Relative DoC is on the y-axis and amplicons are on the x-axis.](1415-4757-GMB-1678-4685-GMB-2018-0092-gf02){#f2}

Sensitivity and specificity were calculated (overall and for each gene) and compared with results obtained by standard Sanger sequencing. False negative and positive overall rates were also calculated. To assess reproducibility of the assay, we measured concordance between independent runs using relative DoC.

Sanger sequencing
-----------------

Sanger sequencing was performed for confirmation of all variants, to fill the regions missed by the custom panel design and low-coverage regions, and for the analysis of clinical utility. gDNA was amplified using specific primers designed for the free software Primer3 v.0.4.0. (available upon request). Amplicons were sequenced by both ends using the Big Dye Terminator v3.1 cycle sequencing kit (Thermo Fisher Scientific), and fragments were resolved on an ABI 3500 DNA Analyzer (Thermo Fisher Scientific). Analysis of results was performed with the BioEdit v7.2.5 free software.

Results
=======

Run metrics
-----------

Our designs generated a total of 73 and 118 amplicons for Panel A and B, respectively. Mean amplicon read length was 150-180 bp. Sequencing of genes generated reads in the range of 69,000 to 7,600 per sample. An evenly distributed mean depth of coverage for both panels was achieved and a mean of 95% targeted bases were covered at least 100X. The other run metrics are summarized in [Table 1](#t1){ref-type="table"}.

###### Performance characteristic for both LSDs panels

  Panel   Breadth of coverage   Mapped reads per sample   On target     Mean depth (X)   Uniformity    \% Target bases covered                  
  ------- --------------------- ------------------------- ------------- ---------------- ------------- ------------------------- -------------- ---------------
  A       97.74%                76,729 ± 31195            0.95 ± 0.02   812 ± 339        0.91 ± 0.06   98.66 ± 0.49              95.55 ± 2.17   55.06 ± 18.08
  B       99.67%                69,044 ± 26566            0.86 ± 0.05   498 ± 198        0.98 ± 0.01   99.72 ± 0.14              94.71 ± 6.41   56.42 ± 25.39

Coverage analysis
-----------------

An overview on coverage for all analyzed samples is shown in [Figure 1](#f1){ref-type="fig"}. Although the coverage for *GAA* and *SMPD1* was expected to be 94.54 and 100%, respectively, the actual mean coverage was found to be 92.46 and 97.22%. The coverage analysis demonstrated two regions poorly covered in these genes, as shown in more detail in Figures S1 and S2. Unfortunately, the low covered region contained the location of the c.573delT (p.Ser192fs) *SMPD1* mutation. The actual coverage for all the other genes was as expected to be 100% based on probe design.

Sensitivity
-----------

To assess the analytical sensitivity of the panels ([Tables 2](#t2){ref-type="table"} and [3](#t3){ref-type="table"}), we compared the results obtained by Sanger sequencing to those obtained by TNGS, including as many different types of variations as possible: nonsense, missense, small deletions, small insertions, splicing, and intronic variants. A total of 57 variants (pathogenic and polymorphisms) were analyzed ([Table 4](#t4){ref-type="table"}). We also identified their correct zygosity status (data not shown).

###### Analytical sensitivity, specificity, FN and FP rates for both TNGS panels.

  Panel   Pathogenic variants   Polymorphism NGS/Sanger   Sensitivity          Specificity   FN rate   FP rate
  ------- --------------------- ------------------------- -------------------- ------------- --------- ---------
  A       17/17                 8/8                       100% (25/25)\*       99.96%        0.000%    0.040%
  B       20/22                 10/10                     93.75% (30/32)\*\*   99.97%        0.063%    0.033%

\*95% CI=0.875-1; \*\*95%CI=0.8091-0.9837, FN: false negative, FP: false positive

###### Analytical sensitivity and specificity for each gene in our gene panels.

  Panel   Gene      Sensitivity     Specificity
  ------- --------- --------------- --------------------
  A       *GLA*     100% (10/10)    100% (1398/1398)
          *NAGA*    100% (3/3)      100% (1381/1381)
          *GAA*     100% (12/12)    99.89% (2987/2990)
          *LAMP2*   n.d\*           100% (1707/1707)
  B       *NPC1*    100% (8/8)      100% (4265/4265)
          *NPC2*    100% (1/1)      100% (5521/5521)
          *GBA1*    83.3% (5/6)     100% (1875/1875)
          *LIPA*    100% (4/4)      100% (1462/1462)
          *SMPD1*   91.7% (11/12)   99.8% (2775/2780)
          *CHIT1*   100% (1/1)      100% (1936/1936)
          *PSAP*    n.d\*           100% (2184/2184)

n.d\*: not determined because there were no positive controls with variant pathogenic in this gene.

Our assay identified precisely all recurrent mutations for LSDs, except two in Panel B. For this panel, the limitations were the inability to detect (1) *SMPD1* c.573delT, p.Ser192fs, located in a region with low coverage, and (2) *GBA1* c.\[1448T \> G; 1483G \> C; 1497G \> C\], p.\[Leu444Pro;Ala456Pro,Val460Val\] ([Tables 2](#t2){ref-type="table"} and [4](#t4){ref-type="table"}).

###### Variants detected in this study by TNGS and Sanger sequencing.

  Gene      Sequence reference   Location        cDNA change                              Protein change                          dbSNP                          Mutation type    NGS detected
  --------- -------------------- --------------- ---------------------------------------- --------------------------------------- ------------------------------ ---------------- --------------
  *GLA*     NM_000169            Exon 01         c.32delG                                 p.Gly11fs                               \-                             Deletion         Yes
                                 Exon 01         c.4C \> T                                p.Gln2Ter                               \-                             Nonsense         Yes
                                 Exon 01         c.167G \> A                              p.Cys56Tyr                              \-                             Missense         Yes
                                 Exon 02         c.334C \> T                              p.Arg112Cys                             rs104894834                    Missense         Yes
                                 Exon 03         c.456C \> A                              p.Tyr152Ter                             \-                             Nonsense         Yes
                                 Exon 04         c.605G \> A                              p.Cys202Tyr                             rs869312344                    Missense         Yes
                                 Exon 05         c\. 644A \> G                            p.Asn215Ser                             rs28935197                     Missense         Yes
                                 Exon 05         c.776C \> G                              p.Pro259Arg                             \-                             Missense         Yes
                                 Exon 05         c\. 790G \> T                            p.Asp264Tyr                             rs190347120                    Missense         Yes
                                 Exon 07         c.1102G \> A                             p.Ala368Thr                             rs144994244                    Missense         Yes
  *NAGA*    NM_000262.2          Exon 03         c\. 279G \> A                            p.Pro93Pro                              rs133369                       Missense         Yes
                                 Exon 06         c.720G \> A                              p.Gln240Gln                             \-                             Missense         Yes
                                 Exon 08         c.973G \> A                              p.Glu325Lys                             rs121434529                    Missense         Yes
  *GAA*     NM_001079804         Intron 01       c.-32-13T \> G                           \-                                      rs386834236                    Splicing         Yes
                                 Exon 03         c.596A \> G                              p.His199Arg                             rs1042393                      Missense         Yes
                                 Exon 03         c.668G \> A                              p.Arg223His                             rs1042395                      Missense         Yes
                                 Intron 8        c.1327-18A \> G                          \-                                      rs2278619                      Intron variant   Yes
                                 Exon 09         c.1374C \> T                             p.Tyr458Tyr                             rs1800305                      Missense         Yes
                                 Exon 10         c.1465G \> A                             p.Asp489Asn                             rs398123169                    Missense         Yes
                                 Exon 10         c.1504A \> G                             p.Met502Val                             rs376067362                    Missense         Yes
                                 Exon 14         c.1905C \> A                             p.Asn635Lys                             \-                             Missense         Yes
                                 Exon 14         c.1941C \> G                             p.Cys647Trp                             \-                             Missense         Yes
                                 Intron 14       c.2040+20A \> G                          \-                                      rs2304836                      Intron variant   Yes
                                 Exon 15         c.2065G \> A                             p.Glu689Lys                             rs1800309                      Missense         Yes
                                 Exon 18         c.2560C \> T                             p.Arg854Ter                             rs121907943                    Nonsense         Yes
  *NPC1*    NM_000271.4          Exon 02         c.114_122del GAGGTACAA                   p.Lys38_Tyr40del                        \-                             Deletion         Yes
                                 Exon 05         c.530G \> A                              p.Cys177Tyr                             rs80358252                     Missense         Yes
                                 Exon 5,∐8,∐12   c.\[547G \> A;1093T \> C;1937G \> A\]    p.\[Ala183Thr;Ser365Pro;Arg646His\]     rs111256741,∐-,∐ rs112387560   Missense         Yes
                                 Exon 20         c.3019C \> G                             p.Pro1007Ala                            rs80358257                     Missense         Yes
                                 Exon 21         c.3104C \> T                             p.Ala1035Val                            rs28942107                     Missense         Yes
                                 Exon 21         c.3182T \> C                             p.Ile1061Thr                            rs80358259                     Missense         Yes
                                 Intron 22       c.3477+3 insCA                           \-                                      \-                             Insertion        Yes+
                                 Exon 24         c.3662_3662delT                          p.Phe1211fs                             \-                             Deletion         Yes
  *NPC2*    NM_006432            Exon 01         c.58G \> T                               p.Glu20Ter                              rs80358260                     Nonsense         Yes
  *GBA1*    NM_001005742         Exon 07         c.850C \> A                              p.Pro245Thr                             \-                             Missense         Yes
                                 Exon 07         c.982_983insTGC                          p.Leu327dup                             rs121908298                                     Yes
                                 Exon 09         c.1226A \> G                             p.Asn370Ser                             rs76763715                     Missense         Yes
                                 Exon 09         c.1251G \> C                             p.Trp378Cys                             \-                             Missense         Yes
                                 Exon 10         c.1448T \> G                             p.Leu444Pro                             rs421016                       Missense         Yes
                                 Exon 10         c.\[1448T \> G;1483G \> C;1497G \> C\]   p.\[Leu444Pro; Ala456Pro; Val460Val\]   \-                             Missense         No
  *LIPA*    NM_001127605         Exon 02         c.67G \> A                               p.Gly23Arg                              rs1051339                      Missense         Yes
                                 Exon 08         c.894G \> A                              p.Glu298Glu                             rs116928232                    Missense         Yes
                                 Exon 10         c.1204G \> A                             p.Gly342Arg                             \-                             Missense         Yes
                                 Intron 05       c.539-5C \> T                            \-                                      rs2297472                      Intron variant   Yes
  *SMPD1*   NM_000543            Exon 01         c.107T \> C                              p.Val36Val                              rs1050228                      Missense         Yes
                                 Exon 02         c.338G \> A                              p.Arg113His                             rs149770879                    Missense         Yes
                                 Exon 02         c.573delT                                p.Ser192fs                              rs727504167                    Deletion         No
                                 Exon 02         c.636T \> C                              p.Asp212Asp                             rs7951904                      Missense         Yes
                                 Exon 02         c.690C \> G                              p.Arg230Arg                             \-                             Missense         Yes
                                 Exon 02         c.714A \> G                              p.Ala238Ala                             rs2682091                      Missense         Yes
                                 Exon 02         c.739G \> A                              p.Gly247Ser                             rs587779408                    Missense         Yes
                                 Exon 06         c.1522GC                                 p.Gly508Arg                             rs1050239                      Missense         Yes
                                 Exon 06         c.1749G \> A                             p.Ser583Ser                             rs35098198                     Missense         Yes
                                 Exon 06         c.1805G \> C                             p.Arg602Pro                             \-                             Missense         Yes
                                 Exon 06         c.1805G \> A                             p.Arg602His                             rs370129081                    Missense         Yes
                                 Exon 06         c.1826_1828delGCC                        p.Arg608del                             rs120074118                    Deletion         Yes
  *CHIT1*   NM_003465.2          Exon 04         c.304G \> A                              p.Gly102Ser                             rs2297950                      Missense         Yes

+: new mutation, confirmed by Sanger sequencing.

Specificity
-----------

Of all sequenced DNA samples, we identified threee false positives in panel A (3 in 7476 true negatives) and five false positives in panel B (5 in 15,054 true negatives), resulting in a specificity value of 99.96% (95%CI=0.998-0.999) and 99.97% (95%CI=0.9992-0.999), respectively ([Table 2](#t2){ref-type="table"}). Specificity by gene is shown in [Table 3](#t3){ref-type="table"}. These false positives were located in low coverage regions, which are prone to sequencing errors.

Reproducibility
---------------

To determine the reproducibility of our assay, we sequenced 24 samples divided in three independent runs for Panel A, and 34 samples divided in four independent runs for Panel B ([Figure 3](#f3){ref-type="fig"}).

![Reproducibility of assays. (A) Mean relative DoC at 30 amplicons (*GAA* gene) of 8 different samples sequenced in 3 different assay runs; (B) Mean relative DoC at 16 amplicons (*SMPD1* gene) of 8-9 different samples sequenced in 4 different assay runs. Error bars represent standard deviation.](1415-4757-GMB-1678-4685-GMB-2018-0092-gf03){#f3}

Clinical Utility Assessment
---------------------------

### Case 1

A 15-year-old male patient with suspicion of having a LSD was referred to our service via NPC Brazil Network. The main clinical findings were unexplained hepatosplenomegaly and myelogram with presence of numerous histiocytes. Several biochemical assays were performed to reach a diagnosis, including measurement of oxysterol and activity of chitotriosidase, lysosomal acid lipase, and b-galactosidase as reference enzymes that were all within normal ranges. Filipin test was inconclusive. Eventually, NPA/B was suspected and ASM enzyme activity was tested in cultured skin fibroblasts, resulting in 1.25 nmol/h/mg protein (reference value: 49-72), indicating NPA/B disease. Due to several factors, like request of new samples for the biochemical assays, it took approximately 12 months to reach this biochemical diagnosis. Panel B, which includes genes related to LSD with hepatosplenomegaly as common clinical manifestation, was utilized as second-tier diagnostic approach. We found two pathogenic variants in *SMPD1*, both confirmed by Sanger sequencing: p.Arg610del (c.1826_1828delGCC) (rs120074118) and p.Asp420fs (c.1259delA), the latter being a novel, unreported mutation and not found in controls (n=32).

### Case 2

A 21-month-old patient, daughter of consanguineous parents who presented macrocephaly and hepatosplenomegaly as main clinical features, high cholesterol (228 mg/dL) and triglycerides (492 mg/dL) levels, elevated liver enzymes (GGT: 137 IU/L; TGP: 256 IU/L) as well as low levels of sphingomyelinase activity, was referred for molecular analysis of *SMPD1* gene. TNGS (Panel B) revealed the homozygous small deletion p.Leu474fs (c.1420_1421delCT), which was reported previously as being pathogenic (rs398123476).

### Case 3

A 21-year-old female, child of a non-consanguineous marriage, with diagnosis of hypertrophic cardiomyopathy at 18 years of age and with previous diagnosis of Danon disease, was referred to our service for mutation analysis of the *LAMP2* gene. TNGS (Panel A) detected the hemizygous variant p.Asn242fs (c. 725delA), a novel pathogenic variant.

### Case 4

A 16-year-old male with suspicion of Danon disease due to hypertrophic cardiomyopathy with anomalous pathway, presented intellectual deficiency, proximal myopathy, and alterations in liver tests. As in case 3, Panel A was used, detecting the hemizygous variant c.741+1G \> A, described as pathogenic (HGMD CS003703).

Discussion
==========

Due to various reasons, such as wide clinical and genetic heterogeneity, LSDs are difficult to diagnose, and it can take several years to reach a final diagnosis ([@B25]; [@B14]). Even if no treatment is available for many of these disorders, genetic diagnosis has potential benefits, such as predicting the prognosis,and allowing genetic counselling and family screening. Recent studies highlight the clinical utility of TNGS technology for genetic diagnosis of LSDs ([@B27]; [@B7]; [@B13]). Although there are some drawbacks to TNGS, such as the inability to detect large indels and structural variants, there are several advantages in applying this approach early in the investigation of patients with LSDs, like high coverage, completeness, low rate of incidental finding, and the potential to reduce the diagnostic delay. TNGS assays involve various technical steps, starting from sample preparation to analysis and data interpretation, and each one requires full validation. We presented data on the development and validation of two gene panels, designed following the criteria of overlapping clinical manifestations, to be offered as a diagnostics option by a reference center of rare diseases ([Figure 1](#f1){ref-type="fig"}). Prior to TNGS, an enrichment step of the genes included in the panel is necessary through capture approaches based on hybridization or PCR-based strategies. The latter one is especially suitable for the investigation of regions with less than 100 kb, has versatile design, and is the most convenient for analysis of genes with pseudogenes due to its high specificity, sensitivity, and reproducibility ([@B4]). Despite some reported disadvantages for this approach (time-consuming, uneven coverage of the target regions due to unequal PCR efficiency across the various amplicons, allelic dropout, and difficulties to detect large deletion/insertion events), Ion Ampliseq targeted technology utilizes a PCR-based method (high throughput multiplex PCR) for this purpose, overcoming some of the limitations and providing high specificity (here, 99.96% and 99.97%) and uniformity (91%-98% for both panels).

From the run metrics results, we can conclude that all samples were uniformly covered at depths that exceed the minimum coverage required (100 X) for accurate calling of variants. The bioinformatics pipeline applied here demonstrated high sensitivity for Panel A (sensitivity 100%) and Panel B (sensitivity 93.75%) ([Table 1](#t1){ref-type="table"}). The use of normal controls (n=3) allowed the identification of eight platform-specific false positive variants, which were filtered from subsequent analyses. A high reproducibility was observed revealing a high concordance between independent runs.

Inadequate coverage regions were identified by coverage plots ([Figure 2](#f2){ref-type="fig"}), and these regions werfe completed by Sanger sequencing. A technical difficulty encountered was related to enrichment of some targets and, as a consequence, low sequence coverage was found. This was observed at two targets corresponding to the *GAA* and *SMPD1* genes. A high GC-content region (70%) was probably the main reason why the GAA amplicon was poorly covered (\~20X). For *SMPD1*, a low-covered amplicon (\~30X) was identified, showing both a GC-content of 66% and a homopolymeric region within the target. These are well-recognized limitations of NGS sequencing. As recommended by the American College of Medical Genetics, both tests achieved a 100% breadth of coverage when complemented with gold-standard DNA sequencing that improves clinical sensitivity.

Another major limitation of Panel B was the inability to detect the *RecNci*I allele, c.\[1448T \> G; 1483G \> C; 1497G \> C\]/ p.\[Leu444Pro;Ala456Pro,Val460Val\]. High sequence similarity between functional genes and their pseudogenes can make the detection of genuine mutation difficult due to the ambivalent mapping in the analysis of NGS data, which cannot always be avoided. Sanger sequencing is generally used to elucidate the correct variant mapping ([@B4]). In our study, the presence of *GBAP1*, a highly homologous *GBA1* pseudogene, complicated sequencing analysis by NGS, with the *RecNci*I allele being particularly difficult to assess since mutant bases in *GBA1* (exon 10) are the wild type sequence in its pseudogene. Panel B failed to detect this allele, representing a case of false negative when present, because variant-containing reads align to homologous loci. Our strategy to infer the presence of *RecNci*I was based on the employment of a global alignment strategy, analyzing the DoC of exon 10 *GBA1* and the homologous *GBAP1* region. We observed that in the presence of the *Rec* allele an uneven reads distribution was observed due to the exclusive alignment of variant-containing reads with *GBAP1*. As examples: (a) for homozygous N370S, we observed a DoC of 369 X for *GBA1* exon 10 and 370X for *GBAP1* homologous region; (b) in the case of compound heterozygosity (N370S/*RecNci*I) for exon 10 *GBA1*, a DoC of 144X and 313X for *GBAP1* was observed. Therefore, the presence of this *Rec* allele was inferred, but Sanger sequencing using a specific primer pair for exon 10 was required for confirmation of this inference.

Clinical utility assessment was performed. Two pathogenic variants were found, *SMPD1* p.Asp420fs (c.1259delA) and *LAMP2* p.Asn242fs (c. 725delA), demonstrating that our TNGS panel is a sensitive tool, with faster turnaround times for provision of results, and relative low cost (\~USD 320 per sample) when compared with Sanger sequencing of individual genes, and showing the potential role for diagnosis of LSDs in our Medical Genetics Service.

In conclusion, TNGS technology can be used for the simultaneous testing of a broad range of SNPs and indels, being a fast, accurate, and cost effective method for the diagnosis of selected LSDs. It allows faster diagnosis and earlier treatment of patients, contributing to reduce the morbidity of the diseases and improve patient survival and quality of life.
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